RVMD FY 2018 Earnings — Revolution Medicines, Inc. Revenue & Financial Results | Market Cap Arena

RVMDRevolution Medicines, Inc.

$19B

FY 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$20M

Gross Profit

$20M100.0% margin

Operating Income

-$40M-200.0% margin

Net Income

-$42M-207.2% margin

EPS (Diluted)

$-1.15

Cash Flow

Operating Cash Flow

$1M

Free Cash Flow

-$286,000

Stock-Based Comp.

$855,000

Balance Sheet

Total Assets

$171M

Total Liabilities

$74M

Stockholders' Equity

$97M

Cash & Equivalents

$70M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$20M	$0	—
Gross Profit	$20M	-$27M	+175.8%
Operating Income	-$40M	-$31M	-29.6%
Net Income	-$42M	-$31M	-34.3%